Spain’s biotech count jumps 10.4% as sector eyes new capital

Spain’s biotech sector is expanding at a pace that outstrips much of Europe. The 2025 AseBio Report, released this week, counted 1,119 dedicated biotech companies in the country, a 10.4% increase from the previous year. That growth puts Spain on track to rival more established hubs in sheer numbers, if not yet in deal size.

The jump isn’t just about volume. AseBio’s data suggests capital is flowing more freely than before, though the report stops short of detailing how much is going to early-stage versus growth rounds. For founders and investors, the question is whether this expansion is sustainable—or if it’s setting up a wave of startups that will struggle to secure follow-on funding. Spain’s biotech scene has long been defined by academic spinouts and small teams; scaling those into companies that can attract larger rounds remains the sector’s biggest hurdle.

What’s driving the growth? Part of it is policy. Spain’s government has ramped up support for science-driven startups, particularly in therapeutics and agritech. The country’s strong research institutions continue to spin out promising science, and a handful of success stories have given local investors more confidence. Still, the ecosystem lacks the deep-pocketed VC firms and corporate backers that fuel later-stage rounds elsewhere.

The timing matters. When we covered global biotech funding last month, the sector was holding steady at $36–40 billion annually, even as AI startups dominated venture capital flows. Spain’s growth suggests biotech is carving out its own space, but it’s not clear how much of that capital is reaching the region. Most of the country’s biotech funding still comes from public sources or European grants, with only a fraction from private investors. That dynamic could shift if more Spanish startups hit clinical milestones or ink partnerships with larger players, but for now, the pipeline feels top-heavy with pre-revenue companies.

For founders, the message is mixed. The rise in company count is a sign of health, but it also means more competition for talent and capital. The startups that stand out will likely be those that can bridge Spain’s academic strengths with commercial discipline—something the country’s ecosystem has historically struggled with. Investors, meanwhile, may see opportunity in the sheer volume of new companies, but they’ll need to be selective. The real story isn’t just that Spain has more biotech startups; it’s whether any of them can become the next breakout success.

What to watch next? AseBio’s next report will likely break down funding by stage, which could reveal whether the growth is concentrated in seed rounds or if later-stage money is finally trickling in. Until then, the sector’s expansion looks more like a numbers game than a funding boom.

Sources: european-biotechnology.com